(L-R) Dr. Bailey; Paul Pharris, sales representative; Mark Anderson, regional manager in San Antonio; and Thad Zak, sales representative
Printer Friendly Format

The Health Science Center division of cardiology trains three interventional cardiology fellows each year – two focus on clinical care and one focuses on translational research in the Janey Briscoe Center for Cardiovascular Research. Historically, one of the fellowships has been funded by the University Health System and two by research grants from Steven R. Bailey, M.D., professor of medicine and radiology at the Health Science Center. In the United States today, 25 percent of all interventional cardiology training positions can not be filled due to inadequate funding.

Boston Scientific is a company that recently provided an unrestricted educational grant in the amount of $45,000 to support the Health Science Center’s interventional cardiology fellows, who provide clinical services for the University Physicians Group, the South Texas Veterans Health Care System and the University Health System. The Boston Scientific donation will enable the interventional cardiology program to continue to provide clinical services and to undertake more research studies. “Only one-third of all fellowship grant applications were funded, so we feel very fortunate,” Dr. Bailey said.

“We’re excited that this company has decided to underwrite the important activity in the Janey Briscoe Center of Excellence in Cardiovascular Research,” Dr. Bailey said. “This grant also is a testament to the strength of the educational program offered by the interventional cardiology faculty, including Drs. Marc Feldman, Devang Patel, Umesh Arora and Robert Chilton.

He recently welcomed (L-R) Paul Pharris, sales representative; Mark Anderson, regional manager in San Antonio; and Thad Zak, sales representative, for a check presentation outside the catheterization laboratories at University Hospital.


Information from bostonscientific.com

Boston Scientific is committed to advancing the practice of less-invasive medicine. Today, the company is investigating a number of innovative technologies, including ones that may restore blood flow to heart muscles damaged by cardiovascular disease using gene therapy or adult stem cells, as well as replacing aortic valves using percutaneous techniques.
Boston Scientific’s interventional cardiology business is a leading developer of medical technologies used to diagnose and treat cardiovascular disease and other cardiovascular disorders.
Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 16,000 employees and revenue of $5.6 billion in 2004. For 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The company’s products help physicians and other medical professionals improve their patients’ quality of life by providing alternatives to surgery that minimize risk, cost, trauma, aftercare and procedure time.